Aspirin May Save Your Liver

Timestamps:
00:00 Intro
01:07 Is Aspirin Protective?
01:56 Is It Linearly Protective Over Time?
03:12 What is the Best Dose?
03:26 Mechanisms
04:38 Synergies

👉🏻 Ways to support and save (affiliate links):
- LA Pump: https://lapump.com/?wpam_id=13 Get 10% OFF with code LONGLEO
- Nurosym: https://nurosym.com Discount Code: LucieC5
-CosmicNootropic: https://cosmicnootropic.com?coupon-code=319 Get 10% OFF with code LUCIE
- Amazon Store: Shop items Leo personally recommended and used https://www.amazon.com/shop/leoandlongevity?ref=ac_inf_tb_vh

🔗 Connect & Explore 🔗
JOIN THE COMMUNITY:
Reddit ▶ The Long-Lived Community / thelonglived
Telegram ▶ https://t.me/+k4x31DY9tgIwM2Fh
TikTok ▶ https://www.tiktok.com/@leoandlongevity?_t=8hXP1SML0LG&_r=1
GENETIC ANALYSIS WAITLIST: Website ▶ https://www.yourgenetically.com/
OTHER CHANNELS
Lucie ▶ / @luciec.7692
Kids ▶ / @bilinguini

🏷️ Leo's personal book collection now on eBay: https://www.ebay.com/usr/colous7

Citations:
1 Farrell, G. C., Wong, V. W. S., & Chitturi, S. (2013). NAFLD in Asia—as common and important as in the West. Nature reviews Gastroenterology & hepatology, 10(5), 307-318.
2 Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013). From NAFLD to NASH to cirrhosis—new insights into disease mechanisms. Nature reviews Gastroenterology & hepatology, 10(11), 627-636.
3 Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021). Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nature Reviews Gastroenterology & Hepatology, 18(4), 223-238.
4 Tan, R. Z. H., Lockart, I., Abdel Shaheed, C., & Danta, M. (2021). Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 54(4), 356-367.
5 Liao, Y. H., Hsu, R. J., Wang, T. H., Wu, C. T., Huang, S. Y., Hsu, C. Y., ... & Liu, D. W. (2020). Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. BMC gastroenterology, 20(1), 1-10.
6 Wang, S., Yu, Y., Ryan, P. M., Dang, M., Clark, C., Kontogiannis, V., ... & Zhang, Y. (2020). Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacological research, 151, 104585.
7 Cheng, A. S., Chan, H. L., Leung, W. K., To, K. F., Go, M. Y., Chan, J. Y., ... & Sung, J. J. (2004). Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Modern Pathology, 17(10), 1169-1179.
8 Yuan, Z., Zhao, J., Wang, Z., Ren, G., Zhang, Z., & Ma, G. (2020). Effects of aspirin on hepatocellular carcinoma and its potential molecular mechanism. J buon, 981-6.
9 Rivas-Estilla, A. M., Bryan-Marrugo, O. L., Trujillo-Murillo, K., Pérez-Ibave, D., Charles-Niño, C., Pedroza-Roldan, C., ... & Rincón-Sánchez, A. R. (2012). Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells. American Journal of Physiology-Gastrointestinal and Liver Physiology, 302(11), G1264-G1273.
10 Ríos-Ibarra, C. P., Lozano-Sepulveda, S., Muñoz-Espinosa, L., Rincón-Sánchez, A. R., Cordova-Fletes, C., & Rivas-Estilla, A. M. G. (2014). Downregulation of inducible nitric oxide synthase (iNOS) expression is implicated in the antiviral activity of acetylsalicylic acid in HCV-expressing cells. Archives of virology, 159(12), 3321-3328.
11 Sitia, G., Aiolfi, R., Di Lucia, P., Mainetti, M., Fiocchi, A., Mingozzi, F., ... & Guidotti, L. G. (2012). Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proceedings of the National Academy of Sciences, 109(32), E2165-E2172.
12 Wang, T., Fu, X., Jin, T., Zhang, L., Liu, B., Wu, Y., ... & Ye, L. (2019). Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma. EBioMedicine, 45, 168-180.
13 Zhang, H., Yang, S., Wang, J., & Jiang, Y. (2021). Blockade of AMPK-Mediated cAMP–PKA–CREB/ATF1 Signaling Synergizes with Aspirin to Inhibit Hepatocellular Carcinoma. Cancers, 13(7), 1738.
14 Abdelmonsif, D. A., Sultan, A. S., El-Hadidy, W. F., & Abdallah, D. M. (2018). Targeting AMPK, mTOR and β-catenin by combined metformin and aspirin therapy in HCC: an appraisal in Egyptian HCC patients. Molecular diagnosis & therapy, 22(1), 115-127.
15 Li, S., Dai, W., Mo, W., Li, J., Feng, J., Wu, L., ... & Guo, C. (2017). By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma. International journal of cancer, 141(12), 2571-2584.

#liver